Multiple members of the RTK/RAS/MAPK pathway have a synthetic lethal interaction with MEK, as they induce tumour resistance to MEK inhibitors by triggering an adaptive reactivation of the MAPK pathway. The gene discussed is MAP2K7; the disease is neoplasm.